Sam68 promotes hepatic gluconeogenesis via CRTC2.

Qiao, Aijun; Zhou, Junlan; Xu, Shiyue; Ma, Wenxia; Boriboun, Chan; Kim, Teayoun; Yan, Baolong; Deng, Jianxin et al. · Nat Commun · 2021

basic_science · Level V

Where this comes from

Abstract

Hepatic gluconeogenesis is essential for glucose homeostasis and also a therapeutic target for type 2 diabetes, but its mechanism is incompletely understood. Here, we report that Sam68, an RNA-binding adaptor protein and Src kinase substrate, is a novel regulator of hepatic gluconeogenesis. Both global and hepatic deletions of Sam68 significantly reduce blood glucose levels and the glucagon-induced expression of gluconeogenic genes. Protein, but not mRNA, levels of CRTC2, a crucial transcriptional regulator of gluconeogenesis, are >50% lower in Sam68-deficient hepatocytes than in wild-type hepatocytes. Sam68 interacts with CRTC2 and reduces CRTC2 ubiquitination. However, truncated mutants of Sam68 that lack the C- (Sam68<sup>ΔC</sup>) or N-terminal (Sam68<sup>ΔN</sup>) domains fails to bind CRTC2 or to stabilize CRTC2 protein, respectively, and transgenic Sam68<sup>ΔN</sup> mice recapitulate the blood-glucose and gluconeogenesis profile of Sam68-deficient mice. Hepatic Sam68 expression is also upregulated in patients with diabetes and in two diabetic mouse models, while hepatocyte-specific Sam68 deficiencies alleviate diabetic hyperglycemia and improves insulin sensitivity in mice. Thus, our results identify a role for Sam68 in hepatic gluconeogenesis, and Sam68 may represent a therapeutic target for diabetes.

Medical subject headings